Wikipedia -WSS

Wikipedia

author：explore 2025-09-07 04:10:05 - browse：5383

A vial of Tofersen injection on the left of its box — The ALS drug tofersen is marketed as Qalsody in the U.S. Biogen

LONDON — Neurologists and patient advocates are up in arms over a policy decision by a U.K. health agency that they say will imperil access to an ALS treatment that’s available in the U.S. and on its way to approval in the European Union.

The medicine in question, Biogen’s tofersen, is designed to treat a rare genetic form of the neurodegenerative disease, accounting for some 2% of all ALS cases. And the issue is how the U.K.’s cost-effectiveness agency has said it would assess the costs and benefits of the therapy.

The agency, the National Institute for Health and Care Excellence, or NICE, has a special pathway for drugs for very rare diseases, which advocates and doctors argue is the route through which tofersen should be reviewed. But NICE has indicated it would review the drug through its standard process, saying it’s because ALS as a whole does not count as a “very rare” disease. That sets a higher bar to clear.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Sepsis can kill a child within hours. Here's how hospitals are fighting back

hotspot

WSS

Biden targets hefty hospital 'facility fees' that often surprise patients

Recent heat wave in the Mediterranean caused by climate change: Study

Is it ever OK for doctors to lie to their patients?

Crowdfunding for medical bills sidesteps core problem, author says

BIO to announce reorganization, senior leaders expected to depart

White House announces new plan to address the growing threat of xylazine in overdose crisis

leisure time

Wikipedia

hotspot

New air purifier tech could be key to improving indoor air quality

Deliver public health messages at the right time

Medical leaders decry Supreme Court decision on affirmative action

GSK’s asthma push continues as drug succeeds in Phase 3 trials

After affirmative action ruling, medical educators look to 'holistic review'

As health system earnings go up, health insurance stocks go down

Malaria cases in Florida and Texas: Here’s what you need to know

Biden targets hefty hospital 'facility fees' that often surprise patients

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

As billionaires fund anti

entertainment

Has Bernie Sanders reached the limit of his pharma bullying effort?

PBM executives asked to testify by House panel

Eisai exec who led development of Alzheimer’s drug to retire

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

Lawmakers grill UnitedHealth CEO on Change cyberattack

Deliver public health messages at the right time

explore

hotspot

hotspot

hotspot